RemeGen Co

RemeGen Co Current Ratio

The Current Ratio of RemeGen Co (688331.SS) as of Oct 26, 2026 is 1.38. In the previous year, Current Ratio was 0.81 — a change of 69.57% (higher).

Current Ratio

1.38

YoY

69.57%

Last updated:

Current Ratio of RemeGen Co is 2025 1.38 . Current Ratio of RemeGen Co was 2024 0.81 . It decreases by 69.57% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Current Ratio of RemeGen Co is 1.38 in 2025.

Current Ratio of RemeGen Co changed from 0.81 to 1.38, representing a 69.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's RemeGen Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RemeGen Co

All Key Metrics — RemeGen Co